ATE485523T1 - Vorhersagen der wundheilung durch harnnitrat- bestimmung - Google Patents
Vorhersagen der wundheilung durch harnnitrat- bestimmungInfo
- Publication number
- ATE485523T1 ATE485523T1 AT02713532T AT02713532T ATE485523T1 AT E485523 T1 ATE485523 T1 AT E485523T1 AT 02713532 T AT02713532 T AT 02713532T AT 02713532 T AT02713532 T AT 02713532T AT E485523 T1 ATE485523 T1 AT E485523T1
- Authority
- AT
- Austria
- Prior art keywords
- wound healing
- patients
- diabetic
- impaired
- nitric oxide
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title abstract 6
- 229910002651 NO3 Inorganic materials 0.000 title abstract 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 title abstract 3
- 210000002700 urine Anatomy 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 4
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000036269 ulceration Effects 0.000 abstract 2
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 abstract 1
- 238000002266 amputation Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 201000002282 venous insufficiency Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/776,926 US6436366B2 (en) | 1999-03-19 | 2001-02-06 | Prediction of wound healing by urinary nitrate assay |
| PCT/US2002/003204 WO2002063308A2 (en) | 2001-02-06 | 2002-02-05 | Prediction of wound healing by urinary nitrate assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485523T1 true ATE485523T1 (de) | 2010-11-15 |
Family
ID=25108752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02713532T ATE485523T1 (de) | 2001-02-06 | 2002-02-05 | Vorhersagen der wundheilung durch harnnitrat- bestimmung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6436366B2 (enExample) |
| EP (1) | EP1360508B1 (enExample) |
| JP (1) | JP2004532389A (enExample) |
| AT (1) | ATE485523T1 (enExample) |
| AU (1) | AU2002245379B2 (enExample) |
| CA (1) | CA2436465A1 (enExample) |
| DE (1) | DE60238032D1 (enExample) |
| ES (1) | ES2354868T3 (enExample) |
| MX (1) | MXPA03007018A (enExample) |
| WO (1) | WO2002063308A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030134332A1 (en) * | 2001-11-28 | 2003-07-17 | Boykin Joseph V. | Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
| WO2004046155A2 (en) * | 2002-11-20 | 2004-06-03 | Boykin Jr Joseph V | Predicting outcome of hyperbaric oxygen therapy treatment with nitric oxide bioavailability |
| US8303995B1 (en) | 2008-06-13 | 2012-11-06 | Board Of Regents, The University Of Texas System | Nitrite formulations and their use as nitric oxide prodrugs |
| CA2844759A1 (en) * | 2011-08-11 | 2013-02-14 | Nathan S. Bryan | Method of measuring and monitoring in vivo nitrite levels |
| BR112014003414B1 (pt) | 2011-08-17 | 2021-09-21 | Board Of Regents, The University Of Texas System | Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico |
| CA2923045C (en) * | 2013-09-04 | 2021-10-19 | Microbaric Oxygen Systems, Llc | Hyperoxic therapy systems, methods and apparatus |
| US9492374B2 (en) | 2015-03-25 | 2016-11-15 | Jose Rafael Salinas Andrade | Composition and method for treatment of ulcers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312663B1 (en) * | 1999-03-19 | 2001-11-06 | Joseph V. Boykin, Jr. | Prediction of diabetes impaired wound healing by urinary nitrate assay |
-
2001
- 2001-02-06 US US09/776,926 patent/US6436366B2/en not_active Expired - Lifetime
-
2002
- 2002-02-05 ES ES02713532T patent/ES2354868T3/es not_active Expired - Lifetime
- 2002-02-05 EP EP02713532A patent/EP1360508B1/en not_active Expired - Lifetime
- 2002-02-05 MX MXPA03007018A patent/MXPA03007018A/es active IP Right Grant
- 2002-02-05 WO PCT/US2002/003204 patent/WO2002063308A2/en not_active Ceased
- 2002-02-05 DE DE60238032T patent/DE60238032D1/de not_active Expired - Lifetime
- 2002-02-05 AU AU2002245379A patent/AU2002245379B2/en not_active Expired
- 2002-02-05 JP JP2002563002A patent/JP2004532389A/ja active Pending
- 2002-02-05 AT AT02713532T patent/ATE485523T1/de not_active IP Right Cessation
- 2002-02-05 CA CA002436465A patent/CA2436465A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6436366B2 (en) | 2002-08-20 |
| WO2002063308A3 (en) | 2002-11-21 |
| ES2354868T3 (es) | 2011-03-18 |
| DE60238032D1 (de) | 2010-12-02 |
| CA2436465A1 (en) | 2002-08-15 |
| MXPA03007018A (es) | 2004-10-15 |
| EP1360508A2 (en) | 2003-11-12 |
| EP1360508B1 (en) | 2010-10-20 |
| US20010047035A1 (en) | 2001-11-29 |
| WO2002063308A2 (en) | 2002-08-15 |
| AU2002245379B2 (en) | 2007-09-06 |
| JP2004532389A (ja) | 2004-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE310957T1 (de) | Vorhersagen ueber von diabetes beeintraechtigte wundheilung | |
| Vowden et al. | The effect of amelogenins (Xelma™) on hard‐to‐heal venous leg ulcers | |
| Margolis et al. | Which venous leg ulcers will heal with limb compression bandages? | |
| Gethin | The significance of surface pH in chronic wounds | |
| Gottrup et al. | Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment | |
| Schorah et al. | Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis | |
| Gray et al. | Moisture vs pressure: making sense out of perineal wounds | |
| DE60113548D1 (de) | Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung | |
| ATE485523T1 (de) | Vorhersagen der wundheilung durch harnnitrat- bestimmung | |
| Trignano et al. | Evaluation of peripheral microcirculation improvement of foot after tarsal tunnel release in diabetic patients by transcutaneous oximetry | |
| DE60203264D1 (de) | Mikrobieller Cellulose-Wundverband zur Behandlung chronischer Wunden | |
| AU2008327712B2 (en) | Diagnostic markers of wound infection | |
| Sun et al. | Evaluation of the healing potential of short-term ozone therapy for the treatment of diabetic foot ulcers | |
| Kapur et al. | Evaluation of effect and comparison of superoxidised solution (oxum) v/s povidone iodine (betadine) | |
| Johansen et al. | Variations in renal threshold for glucose in Type 1 (insulin-dependent) diabetes mellitus | |
| Argirova et al. | Acticoat versus Allevyn as a split-thickness skin graft donor-site dressing: a prospective comparative study | |
| DE60212143D1 (de) | Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera | |
| Agren et al. | Selenium, zinc, iron and copper levels in serum of patients with arterial and venous leg ulcers | |
| Martin et al. | Ulcers caused by bullous morphea treated with tissue‐engineered skin | |
| Stacey | Combined topical growth factor and protease inhibitor in chronic wound healing: Protocol for a randomized controlled proof-of-concept study | |
| Irawan et al. | Hypochlorous acid for wound healing in diabetic rats: effect on MMP-9 and histology | |
| Shah et al. | Evaluation of a bovine 100% native collagen for the treatment of chronic wounds: a case series | |
| Antoszewska et al. | Bioimpedance sensor array for monitoring chronic wounds: Validation of method feasibility | |
| Chen et al. | [Retracted] Effect of Micropower Vacuum Dressing on Promoting Wound Healing in Patients with I‐II Diabetic Foot | |
| GR1001145B (el) | Μεθοδος για την αντιμετωπιση αγγειακων ασθενειων. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |